ROKIT Healthcare introduces the world’s first 3D skin bioprinting platform technology using autologous adipose tissue to regenerate skin while minimizing scar formation.
Adipose tissue is an optimal biomaterial for skin regeneration because adipose tissue contains stromal vascular fraction and extracellular matrix which are two main ingredient in MA-ECM dermis, and 3D bioprinter INVIVO prints minimally processed adipose tissue into a custom shape MA-ECM dermis. Skin regeneration with MA-ECM dermis is achieved by regulating MMPs activity especially MMP13 in both transcription (MT1X, MT2A, MT1E ) and protein level (CEBPB, JUND, EGR2, ZNF117). Also, ECM-M2 macrophage interaction strongly promotes skin regeneration by inducing M2 macrophage to release regenerative cytokines. At the same time, SVF cells from MA-ECM coordinate with M2 macrophage to reorganize the surrounding environment into regenerative condition. Furthermore, MA-ECM bound TIMP3 specifically inactivates MMP13 which is critical in the pathogenic prolongation of chronic wounds. By providing rich ECM originated regenerative environment combined with powerful MMP regulation, ROKIT’s 3D bioprinting MA-ECM skin regeneration platform provides a unique solution to regenerate skin.
“ROKIT Healthcare starts the world’s first 3D bio-printing self-cartilage regenerative clinical trial with Harvard Medical School, Massachusetts General Hospita”– ROKIT Healthcare
Opens up possibilities to regenerate cartilage with self-cell instead of metal artificial joint
Developing 3D cartilage regeneration method beyond the limit of current 2D injection therapy
ROKIT Healthcare(CEO Seo-Whan You) starts a large-scale animal experiment, that develops human long-term regeneration platform, produced an autologous cell cartilage structure with a 3D bio-printer and successfully proved the effect of autologous cartilage regeneration through animal experiments in South Korea, with MGH(Massachusetts General Hospital). The cartilage regeneration procedure using the 3D bio printer developed by Rokit Healthcare Co., Ltd. reproduces the shape of the damaged cartilage tissue from the MRI / CT data in a patient-customized manner. They have applied for domestic and foreign patents last year on using bio ink to regenerate damaged cartilage area with minimal incision.
Conventional injection cartilage therapy has many structural limitations in treating very complex 3-D human cartilage, but since it is an innovative method of regenerating autografts by outputting three-dimensional images of the damaged area correctly, It is a state-of-the-art new medical technology.
Dr. Charles Bragdon, deputy director of the MGH Harris Orthopedics Lab, said that the 3-dimensional cartilage regeneration technique developed at Rokit Healthcare will be a technique that can be used for the treatment of degenerative arthritis caused by aging. He will present the technology at The American Society of Orthopedic Surgeons (AAOS),and willing to collaborate with global cartographic orthopedic surgeons for clinical application studies.
“In the first half year, we will conduct research on human subjects as early as this year.” Yoo Seok-hwan, CEO of Rokit Healthcare, said. They have already confirmed that the cartilage tissue produced by our cartilage regenerating technique is differentiated into hyaline cartilage rather than fibrous cartilage through domestic animal experiments.
ROKIT Healthcare, a company that develops human long-term regeneration platforms, raised KRW 11 billion investments. The company plans to develop a long-term organ regenerative platform and to go public the listing on the KOSDAQ.
According to the venture capital industry, Rokit Healthcare has recently increase capital by issuing new stocks to institutional investors. The investment attraction was conducted for a total of three institutions including Korea Development Bank and Daily Partners including KB Investment, which was an existing investment company. The total investment is 11 billion KRW, which is estimated to have tripled the enterprise value compared to the investment attraction which took place about a year and six months ago. In addition to the investment completed this year, Rokit Healthcare is also undergoing additional institutional investment of approximately KRW 20 billion.
Rokit Healthcare plans to launch a full-scale global commercialization of its long-term renewal platform as a result of this investment inducement. The investment will be used for the development costs of the long-term reconstruction platform such as skin regeneration and cartilage regeneration platform using the 3D bio printer “INVIVO” developed by Rokit Healthcare and company operating funds. In addition, it said that it is concluding negotiations for additional investment of about 20 billion won in the first quarter of 2019.
Rokit Healthcare selected Mirae Asset Daewoo Securities as its managing director in July last year and is spurring the company’s public offering.
Rokit Healthcare is a bio-venture company founded in 2012 by CEO Seok-Hwan Yoo, who was CEO of Celltrion Healthcare. “In 2016, we succeeded in developing and launching INVIVO, the world’s first desktop 3D bio-printer, and is conducting research and development to provide personalized long-term renewable medical services using 3D bio-printers” he said. According to company officials, Rokit Healthcare will launch a skin rejuvenation medical platform service in South Korea and abroad after completing clinical trials for skin regeneration in the first half of this year.
“Rokit health care makes inroads in the human organ reproduction by establishing Tissue Bank”– ROKIT Healthcare
ROKIT Healthcare, a company that develops human long-term regeneration platform, has been granted permission to establish a tissue bank and is currently undergoing an import approval process from the FDA (Food and Drug Administration)
Rokit Healthcare Tissue Bank will donate and distribute cartilage (costal cartilage) that can be transplanted from a postmortem human tissue donor, and use it for long-term regeneration by transplanting and processing into patients who need transplantation or regeneration. .
Yoo Seok-hwan, CEO of Rokit Healthcare, said, “We will work with human organ bank in the US to resolve the shortage of organ donation in South Korea and receive the approval from the pharmacy to provide patients with organ regeneration and rehabilitation. And we hope that the safe supply of human tissue implants will be boosted.”
“This year will be our milestone as we will contribute to stable supply and demand by securing all the safe, self-derived cells and allogenic biomaterials derived from human body by donating tissues through tissue banks.”